Grifols (GIKLY) Other Non-Current Liabilities (2009 - 2025)

Grifols (GIKLY) posted Other Non-Current Liabilities of $138.5 million for Q4 2025, up 12862.92% quarter-over-quarter from $1.1 million in Q4 2024, and up 12862.92% year-on-year from N/an in Q4 2024.

Grifols (GIKLY) Other Non-Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GIKLY) has reported Other Non-Current Liabilities for 16 consecutive years, with $138.5 million the latest figure, recorded in Q4 2025.

  • Other Non-Current Liabilities for Q4 2025 came in at $138.5 million, up 12862.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $138.5 million (up 12862.92% YoY), and the FY2025 annual result was $138.5 million, up 12862.92% from the prior year.
  • Other Non-Current Liabilities was $138.5 million for Q4 2025 at Grifols, up from $1.1 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $138.5 million in Q4 2025 and troughed at $1.1 million in Q4 2024.
  • Average Other Non-Current Liabilities over 5 years is $81.1 million, with a median of $112.3 million recorded in 2022.
  • Year-over-year, Other Non-Current Liabilities plunged 99.15% in 2024 and soared 12862.92% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $27.6 million in 2021, then surged by 306.93% to $112.3 million in 2022, then increased by 12.03% to $125.8 million in 2023, then slumped by 99.15% to $1.1 million in 2024, then jumped by 12862.92% to $138.5 million in 2025.
  • Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $138.5 million in Q4 2025, $1.1 million in Q4 2024, and $125.8 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Grifols - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 138.52 Mn
Dec 31, 2024 1.07 Mn
Dec 31, 2023 125.80 Mn
Dec 31, 2022 112.29 Mn
Dec 31, 2021 27.59 Mn
Dec 31, 2020 32.51 Mn
Sep 30, 2020 661.48 Mn
Mar 31, 2020 543.55 Mn
Dec 31, 2019 8.89 Mn
Sep 30, 2019 497.08 Mn
Dec 31, 2018 6.98 Mn
Sep 30, 2018 500.18 Mn
Jun 30, 2018 96.90 Mn
Mar 31, 2018 529.17 Mn
Dec 31, 2017 6.79 Mn
Jun 30, 2017 85.29 Mn
Dec 31, 2016 5.53 Mn
Sep 30, 2016 97.13 Mn
Jun 30, 2016 132.34 Mn
Dec 31, 2015 5.46 Mn